尤瑞克林治疗急性脑梗死的临床疗效和安全性研究

目的探讨尤瑞克林对急性脑梗死的临床疗效及安全性。方法选择102例急性脑梗死患者，随机分为尤瑞克林治疗组（51例）和对照组（51例）。治疗组予尤瑞克林0．15PNAU稀释后静脉滴注，同时静脉滴注血栓通；对照组仅予静脉滴注血栓通。两组疗程均为10d。分别在治疗前和治疗后第10日、第90日进行欧洲卒中量表（ESS）评分和Barthel指数（BI）评分。结果治疗后第10日、第90日，治疗组ESS评分和BI评分均明显高于对照组（P〈0．05或0．01），且未见严重不良反应。结论尤瑞克林可以改善急性脑梗死患者的神经功能，不良反应少。

Clinical study of urinary kallidinogenase in the treatment of acute cerebral infarction

Objective To investigate the clinical efficacy of urinary kallidinogenase in the treatment of acute cerebral infarction. Methods One hundred and two patients with acute cerebral infarction were ran- domly divided into two groups： the urinary kallidinogenase treatment group （51 cases） and the control group （51 cases）. All patients in the two groups were given Xueshuantong powder injection through intravenous drip, but only the former group was administered with the diluted urinary kallidinogenase （0. 15 PNAU）. European Stroke Scale （ESS） and Barthel Index （BI） were evaluated before the treatment and on Day 10 and Day 90 af- ter the treatment. Results ESS and BI of urinary kallidinogenase treatment group were markedly higher than those of the control group on Day 10 and Day 90 respectively （ P 〈 0. 05 or 0. 01 ）. Conclusion In the treat- ment of acute cerebral infarction, urinary kallidinogenase is helpful to improve the neurological function with fe- wer adverse reactions.